Medical Marijuana TAA Position Statement on the Use of Medical Marijuana for Tourette Syndrome The Tourette Association of America (TAA) is the leading national non-profit organization in the Cannabinoids have been used for hundred of years for medical purposes. To day, the cannabinoid delta-9-tetrahydrocannabinol (THC) and the cannabis extract nabiximols are approved for the treatment of nausea, anorexia and spasticity, respectively. In Tourette syndrome (TS) several anecdotal reports p …
TAA Position Statement on the Use of Medical Marijuana for Tourette Syndrome
The Tourette Association of America (TAA) is the leading national non-profit organization in the United States working to make life better for all people affected by Tourette Syndrome and Tic Disorders. As part of that mission the TAA has encouraged and funded research into all aspects of Tourette Syndrome including pharmacological, behavioral, and alternative treatments and therapies.
Inquiries about the use of medical marijuana (cannabis) to alleviate the symptoms of Tourette Syndrome have been on the rise. While some adult members of our community have reported reduced tics when using medical marijuana, others have reported adverse reactions or no effect at all. Medical marijuana has two primary chemical components: Delta-9- tetrahydrocannabinol (THC) and Cannabidiol (CBD). Medical marijuana and cannabis-based medications that include THC and cannabis extracts have been reported to reduce symptoms of Tourette Syndrome in small scientific studies, patient reports, and anecdotal case reports. They are currently used to treat adult patients in Germany, Israel and Canada. There is insufficient data to support that CBD, without the addition of THC, is an effective treatment for Tourette Syndrome.
CBD-based oils, capsules, edibles and other formulations have become widely used over the last decade and are available throughout the country and on line. One CBD based medicine was approved in June 2018 by the FDA specifically to treat two rare forms of epilepsy, making it the first federally sanctioned medical use for CBD in the United States. The FDA has supported research of CBD-based medications and the NIH database reflects myriad studies of CBD as a potential treatment for neurological and neuropsychiatric disorders including epilepsy, Parkinson’s Disease, dyskinesia, dystonia, and anxiety. Although there is no
evidence that CBD alone is effective in treating Tourette Syndrome, anxiety is known to increase the frequency and severity of tics and testimonials for CBD as an effective anxiety reducing treatment are numerous.
To better understand the role of medical marijuana in treating Tourette Syndrome and Tic Disorders, the TAA formed a Cannabis Consortium comprised of leading clinicians and researchers in the field. They evaluated the currently available research and data on the safety and efficacy of medical marijuana and cannabis-based medicines, and have advised us that due to the lack of randomized, large scale, placebocontrolled clinical studies, scientific evidence is insufficient to reach a conclusion on the safety and/or the efficacy of medical marijuana for the treatment of Tourette Syndrome and Tic Disorders. In the absence of conclusive medical research, they are especially concerned about medical marijuana in the treatment of
children and adolescents. The Tourette Association of America shares that concern.
Medical marijuana is not regulated by the Food and Drug Administration (FDA) and is not sanctioned under federal law. However, at the time of this writing, 33 states and the District of Columbia have legalized medical marijuana to treat specific conditions including those that cause muscle spasms, seizures, and chronic pain. Several states have specifically approved medical marijuana for the treatment of Tourette Syndrome including Arkansas, Illinois, Minnesota, Missouri, New Jersey, and Ohio. Still other states permit individuals to access medical marijuana providing a physician certifies that no other medications have provided relief. Medical marijuana is dispensed by state regulated dispensaries, under the direction of a pharmacist, and only after a physician certifies that a patient meets that state’s criteria.
The absence of federal laws sanctioning medical marijuana nationwide, as well as its classification as a Schedule I drug, precludes large-scale controlled research studies from being conducted at academic/research institutions in America. In Germany, a large placebo-controlled study designed to investigate the efficacy and safety of cannabis in patients with Tourette Syndrome is currently recruiting participants. The TAA supports efforts to allow research on medical marijuana to move forward in this country as well. The TAA also supports a drug schedule re-evaluation for medical marijuana which may open the way for clinical trials to assess the efficacy of potential new medications to treat Tourette Syndrome.
Many members of our community have pervasive and painful tics and co-occurring conditions that are not well controlled by current FDA approved options. While there are three medications the FDA has specifically approved for the treatment of Tourette Syndrome, their side effects are significant and they are no longer considered a first option for treatment. More commonly, FDA approved medications are administered off label to children, adolescents, and adults, often effectively but perhaps equally often with adverse, sometimes significant, side effects. The Tourette Association of America recently conducted an impact survey which found that 47% of adults and 44% of the parents of children with Tourette Syndrome do not feel their or their children’s symptoms are adequately controlled by existing medications. We recognize the need for more effective treatments to improve the quality of life for all people with Tourette Syndrome and Tic Disorders.
The Tourette Association of America supports increased research and large scale controlled clinical trials by increasing funding and access to medical marijuana. Thus far, the TAA has funded 5 research grants in Canada, Israel and the U.S. on medical marijuana and related drugs that target cannabis pathways, but more research is needed. The TAA also supports the inclusion of Tourette Syndrome as an approved condition in states where medical marijuana is available to adults with other intractable and incurable conditions but urges caution.
Members of our community who choose to explore medical marijuana as a treatment option should only do so with close medical guidance and after carefully considering the potential risks and benefits. The Tourette Association of America neither recommends nor prescribes specific medications including FDA approved pharmaceuticals and medical marijuana.
Treatment of Tourette syndrome with cannabinoids
Cannabinoids have been used for hundred of years for medical purposes. To day, the cannabinoid delta-9-tetrahydrocannabinol (THC) and the cannabis extract nabiximols are approved for the treatment of nausea, anorexia and spasticity, respectively. In Tourette syndrome (TS) several anecdotal reports provided evidence that marijuana might be effective not only in the suppression of tics, but also in the treatment of associated behavioural problems. At the present time there are only two controlled trials available investigating the effect of THC in the treatment of TS. Using both self and examiner rating scales, in both studies a significant tic reduction could be observed after treatment with THC compared to placebo, without causing significant adverse effects. Available data about the effect of THC on obsessive-compulsive symptoms are inconsistent. According to a recent Cochrane review on the efficacy of cannabinoids in TS, definite conclusions cannot be drawn, because longer trials including a larger number of patients are missing. Notwithstanding this appraisal, by many experts THC is recommended for the treatment of TS in adult patients, when first line treatments failed to improve the tics. In treatment resistant adult patients, therefore, treatment with THC should be taken into consideration.
Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM. Müller-Vahl KR, et al. J Clin Psychiatry. 2003 Apr;64(4):459-65. doi: 10.4088/jcp.v64n0417. J Clin Psychiatry. 2003. PMID: 12716250 Clinical Trial.
Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, Emrich HM. Müller-Vahl KR, et al. Pharmacopsychiatry. 2002 Mar;35(2):57-61. doi: 10.1055/s-2002-25028. Pharmacopsychiatry. 2002. PMID: 11951146 Clinical Trial.
Szejko N, Saramak K, Lombroso A, Müller-Vahl K. Szejko N, et al. Neurol Neurochir Pol. 2022;56(1):28-38. doi: 10.5603/PJNNS.a2021.0081. Epub 2021 Oct 28. Neurol Neurochir Pol. 2022. PMID: 34708399 Review.
Müller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U. Müller-Vahl KR, et al. Neuropsychopharmacology. 2003 Feb;28(2):384-8. doi: 10.1038/sj.npp.1300047. Neuropsychopharmacology. 2003. PMID: 12589392 Clinical Trial.
Curtis A, Clarke CE, Rickards HE. Curtis A, et al. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD006565. doi: 10.1002/14651858.CD006565.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821373 Free PMC article. Review.
Roessner V, Eichele H, Stern JS, Skov L, Rizzo R, Debes NM, Nagy P, Cavanna AE, Termine C, Ganos C, Münchau A, Szejko N, Cath D, Müller-Vahl KR, Verdellen C, Hartmann A, Rothenberger A, Hoekstra PJ, Plessen KJ. Roessner V, et al. Eur Child Adolesc Psychiatry. 2022 Mar;31(3):425-441. doi: 10.1007/s00787-021-01899-z. Epub 2021 Nov 10. Eur Child Adolesc Psychiatry. 2022. PMID: 34757514 Free PMC article. Review.
Fuentes-Verdugo E, López-Tolsa GE, Pellón R, Miguéns M. Fuentes-Verdugo E, et al. Psychopharmacology (Berl). 2022 May;239(5):1359-1372. doi: 10.1007/s00213-021-05952-2. Epub 2021 Aug 26. Psychopharmacology (Berl). 2022. PMID: 34436650 Free PMC article.
Nicolini H, Martínez-Magaña JJ, Genis-Mendoza AD, Villatoro Velázquez JA, Camarena B, Fleiz Bautista C, Bustos-Gamiño M, Aguilar García A, Lanzagorta N, Medina-Mora ME. Nicolini H, et al. Front Psychiatry. 2021 May 10;12:664228. doi: 10.3389/fpsyt.2021.664228. eCollection 2021. Front Psychiatry. 2021. PMID: 34040556 Free PMC article.
Kayser RR, Snorrason I, Haney M, Lee FS, Simpson HB. Kayser RR, et al. Cannabis Cannabinoid Res. 2019 Jun 14;4(2):77-87. doi: 10.1089/can.2018.0049. eCollection 2019. Cannabis Cannabinoid Res. 2019. PMID: 32656342 Free PMC article. Review.
Seideman MF, Seideman TA. Seideman MF, et al. J Pediatr Pharmacol Ther. 2020;25(5):401-412. doi: 10.5863/1551-6776-25.5.401. J Pediatr Pharmacol Ther. 2020. PMID: 32641910 Free PMC article. Review.